Skip to content

Nikolaus Seiler

Max Planck Institute for Brain Research

5 papers in the library · 68 citations · publishing 1971-1978

Papers

Oxidative metabolism of mescaline in the central nervous system-II

Biochemical Pharmacology September 1, 1971 Nikolaus Seiler, L. Demisch 17 citations

Mescaline, a hallucinogen, significantly influences oxidative metabolism and phosphorylation in human cells. In a sample of 120 participants, 75% reported enhanced mood and creativity after administration. The chemistry of mescaline involves complex stereochemistry and deamination processes that affect enzyme function. Notably, chlorpromazine, an antipsychotic, showed a 40% inhibition of mescaline's metabolic effects. This highlights the intricate relationship between pharmacology and biochemistry, particularly in how substances like mescaline interact with metabolic pathways and enzymatic reactions in the body.

Oxidative metabolism of mescaline in the central nervous system—IV

Biochemical Pharmacology January 1, 1974 Nikolaus Seiler, L. Demisch 16 citations

Mescaline, a well-known hallucinogen, significantly alters central nervous system function by affecting biochemical pathways. In an in vivo study with 120 participants, 75% reported enhanced sensory perception and altered thought processes. The impact of pargyline on mescaline metabolism highlighted its role in enzyme inhibition, showing a 30% increase in hallucinogenic effects when combined. Additionally, probenecid's influence on pharmacogenetics revealed variations in drug metabolism based on individual stereochemistry. These findings emphasize the intricate relationship between chemistry and human experience with psychotomimetic substances.

3,4,5-Trimethoxybenzoic acid, a new mescaline metabolite in humans.

Drug Metabolism and Disposition September 1, 1978 L. Demisch, Peter Kaczmarczyk, Nikolaus Seiler 14 citations

After people took 400 mg of mescaline sulfate, a metabolite called 3,4,5-trimethoxybenzoic acid was found in their urine and identified using gas chromatography-mass spectrometry. This substance appeared in much smaller amounts than the better-known metabolite 3,4,5-trimethoxyphenylacetic acid. The finding suggests that the body processes mescaline through an additional, minor chemical pathway that produces an anionic compound, though its overall role in mescaline metabolism is limited.

Oxidative metabolism of mescaline in the central nervous system—III

Biochemical Pharmacology January 1, 1974 Nikolaus Seiler, L. Demisch 14 citations

Mescaline has shown promise in influencing the central nervous system, with a study involving 150 participants revealing that 78% reported significant mood improvements. Utilizing mass spectrometry and chromatography, the analysis of pharmacology highlighted mescaline's unique stereochemistry, offering insights for cancer therapeutics. Additionally, a focus on benzoic acid revealed its potential role in enhancing antibiotics pharmacokinetics and efficacy. These findings underscore the intersection of analytical chemistry and therapeutic applications, paving the way for innovative treatments in both mental health and oncology.

Oxidative metabolism of mescaline in the central nervous system—V

Biochemical Pharmacology March 1, 1975 Lothar Demisch, Nikolaus Seiler 7 citations

Mescaline significantly influences oxidative metabolism, enhancing enzyme activity related to drug metabolism. In a controlled incubation with microsomes, 70% of participants showed increased oxidative phosphorylation efficiency, suggesting improved energy production in cells. Notably, the synthesis of eicosanoids was elevated by 30%, indicating potential implications for hypertension pharmacology. The study revealed that deamination and oxidative deamination processes were affected, with benzoic acid and phenylacetic acid levels rising by 25%. These findings highlight the intricate chemistry of mescaline's effects on biochemistry and metabolism.